FTM
BECOME A MEMBER
() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Tag Archives: PILL

  • Home
  •  | 
  • Tag Archives: "PILL"

Canntab announces collaboration and profit sharing agreement with FSD Pharma to produce and market oral dose delivery platforms

Canntab announces collaboration and profit sharing agreement with FSD Pharma to produce and market oral dose delivery platforms
Canntab Therapeutics Limited (CSE:PILL) ("Canntab"), a leader in the rapidly growing cannabis pill market, is pleased to announce that it has entered into a non-binding letter of intent (the "LOI") with FSD Pharma Inc. (CSE: HUGE) ("FSD Pharma"), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations. Under the terms of the LOI, FSD Pharma will assist Canntab to obtain a license to process and sell cannabis products pursuant to the Cannabis Act (the "License"), and will provide Canntab with space at its 620,000 square foot facility (the "FSD Facility"), which is located just one hour east of Toronto in Cobourg, Ontario (the "Transaction").
Read more

Canntab: Advancing Cannabinoid Research in Australia

Canntab: Advancing Cannabinoid Research in Australia
CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication of an article covering Canntab Therapeutics Ltd. (CSE:PILL) (CNSX:PILL) (PILL.CN) and its Canntab XR cannabinoid tablets that offer pharmaceutical-grade formulation to help doctors and patients control their dosing, as well as help researchers better study the drug in clinical trials. The company is pioneering this work in a new Australian joint venture that investors may want to note when looking for investment opportunities in the medical space.
Read more